The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Targeting the p300/CBP Axis in Lethal Prostate Cancer
Open accessAbstract
Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of AR (AR-SV). Inhibitors of transcriptional coactivators that regulate AR activity, including the paralog histone acetyltransferase proteins p300 and CBP, are attractive therapeutic targets for lethal prostate cancer. Herein, we validate targeting p300/CBP as a therapeutic strategy for lethal prostate cancer and describe CCS1477, a novel small-molecule inhibitor of the p300/CBP conserved bromodomain. We show that CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases AR- and C-MYC–regulated gene expression. In AR-SV–driven models, CCS1477 has antitumor activity, regulating AR and C-MYC signaling. Early clinical studies suggest that CCS1477 modulates KLK3 blood levels and regulates CRPC biopsy biomarker expression. Overall, CCS1477 shows promise for the treatment of patients with advanced prostate cancer. Significance: Treating CRPC remains challenging due to persistent AR signaling. Inhibiting transcriptional AR coactivators is an attractive therapeutic strategy. CCS1477, an inhibitor of p300/CBP, inhibits growth and AR activity in CRPC models, and can affect metastatic CRPC target expression in serial clinical biopsies. See related commentary by Rasool et al., p. 1011. This article is highlighted in the In This Issue feature, p. 995
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,116
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationThe Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
Self-citationEnzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Abiraterone for prostate cancer not previously treated with hormone therapy
James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702900 · Cited by 1,801
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Genomic correlates of clinical outcome in advanced prostate cancer
Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., Cieslik, M., Benelli, M., Robinson, D., Van Allen, E. M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902651116 · Cited by 1,372
Self-citationRecent Global Patterns in Prostate Cancer Incidence and Mortality Rates
Culp, M. B., Soerjomataram, I., Efstathiou, J. A., Bray, F., & Jemal, A. (2020) · European Urology · doi:10.1016/j.eururo.2019.08.005 · Cited by 1,364
p300/CBP proteins: HATs for transcriptional bridges and scaffolds
Chan, H. M., & La Thangue, N. B. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.13.2363 · Cited by 1,092
Hu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M., Yang, R., Escara-Wilke, J., Wilder-Romans, K., Dhanireddy, S., Engelke, C., et al. (2014) · Nature · doi:10.1038/nature13229 · Cited by 927
Detre, S., Saclani Jotti, G., & Dowsett, M. (1995) · Journal of Clinical Pathology · doi:10.1136/jcp.48.9.876 · Cited by 880
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Lasko, L. M., Jakob, C. G., Edalji, R. P., Qiu, W., Montgomery, D., Digiammarino, E. L., Hansen, T. M., Risi, R. M., Frey, R., Manaves, V., et al. (2017) · Nature · doi:10.1038/nature24028 · Cited by 858
Kumar, A., Coleman, I., Morrissey, C., Zhang, X., True, L. D., Gulati, R., Etzioni, R., Bolouri, H., Montgomery, B., White, T., et al. (2016) · Nature Medicine · doi:10.1038/nm.4053 · Cited by 738
Li, Y., Chan, S. C., Brand, L. J., Hwang, T. H., Silverstein, K. A. T., & Dehm, S. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3630 · Cited by 680
Scher, H. I., Lu, D., Schreiber, N. A., Louw, J., Graf, R. P., Vargas, H. A., Johnson, A., Jendrisak, A., Bambury, R., Danila, D., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1828 · Cited by 641
Hu, R., Lu, C., Mostaghel, E. A., Yegnasubramanian, S., Gurel, M., Tannahill, C., Edwards, J., Isaacs, W. B., Nelson, P. S., Bluemn, E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3892 · Cited by 583
Fu, M., Wang, C., Reutens, A. T., Wang, J., Angeletti, R. H., Siconolfi-Baez, L., Ogryzko, V., Avantaggiati, M.-L., & Pestell, R. G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000660200 · Cited by 409
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Sharp, A., Coleman, I., Yuan, W., Sprenger, C., Dolling, D., Rodrigues, D. N., Russo, J. W., Figueiredo, I., Bertan, C., Seed, G., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122819 · Cited by 393
Self-citationEnhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation
Raisner, R., Kharbanda, S., Jin, L., Jeng, E., Chan, E., Merchant, M., Haverty, P. M., Bainer, R., Cheung, T., Arnott, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.041 · Cited by 375
A Hormone–DNA Repair Circuit Governs the Response to Genotoxic Insult
Goodwin, J. F., Schiewer, M. J., Dean, J. L., Schrecengost, R. S., de Leeuw, R., Han, S., Ma, T., Den, R. B., Dicker, A. P., Feng, F. Y., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0108 · Cited by 364
Self-citationFu, M., Rao, M., Wang, C., Sakamaki, T., Wang, J., Di Vizio, D., Zhang, X., Albanese, C., Balk, S., Chang, C., et al. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.23.8563-8575.2003 · Cited by 277
CREB-binding protein in androgen receptor-mediated signaling
Aarnisalo, P., Palvimo, J. J., & Jänne, O. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2122 · Cited by 255
Santer, F. R., Höschele, P. P. S., Oh, S. J., Erb, H. H. H., Bouchal, J., Cavarretta, I. T., Parson, W., Meyers, D. J., Cole, P. A., & Culig, Z. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0182 · Cited by 235
CREB Binding Protein Is a Coactivator for the Androgen Receptor and Mediates Cross-talk with AP-1
Frønsdal, K., Engedal, N., Slagsvold, T., & Saatcioglu, F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.48.31853 · Cited by 222
p300 in prostate cancer proliferation and progression.
Debes, J. D., Sebo, T. J., Lohse, C. M., Murphy, L. M., Haugen, D. A. L., & Tindall, D. J. (2003) · PubMed · Cited by 219
Reutens, A. T. (2001) · Molecular Endocrinology · doi:10.1210/me.15.5.797 · Cited by 189
Kron, K. J., Murison, A., Zhou, S., Huang, V., Yamaguchi, T. N., Shiah, Y.-J., Fraser, M., van der Kwast, T., Boutros, P. C., Bristow, R. G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3930 · Cited by 187
Scher, H. I., Graf, R. P., Schreiber, N. A., McLaughlin, B., Lu, D., Louw, J., Danila, D. C., Dugan, L., Johnson, A., Heller, G., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.11.024 · Cited by 182
Serial blood-based analysis of AR-V7 in men with advanced prostate cancer
Nakazawa, M., Lu, C., Chen, Y., Paller, C. J., Carducci, M. A., Eisenberger, M. A., Luo, J., & Antonarakis, E. S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv282 · Cited by 178
Meyer, S. N., Scuoppo, C., Vlasevska, S., Bal, É., Holmes, A. B., Holloman, M., Garcia‐Ibanez, L., Nataraj, S. E., Duval, R., Vantrimpont, T., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.006 · Cited by 169
Self-citationAsangani, I. A., Wilder-Romans, K., Dommeti, V. L., Krishnamurthy, P. M., Apel, I. J., Escara-Wilke, J., Plymate, S. R., Navone, N. M., Wang, S., Feng, F. Y., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0472 · Cited by 158
Welti, J. C., Sharp, A., Yuan, W., Dolling, D. I., Rodrigues, D. N., Figueiredo, I., Gil, V., Neeb, A., Clarke, M., Seed, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3571 · Cited by 156
Self-citationJin, L., Garcia, J., Chan, E., de la Cruz, C., Segal, E., Merchant, M., Kharbanda, S., Raisner, R., Haverty, P. M., Modrusan, Z., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0314 · Cited by 153
Laere, B. D., van Dam, P., Whitington, T., Mayrhofer, M., Diaz, E. H., den Eynden, G. V., Vandebroek, J., Del‐Favero, J., Laere, S. V., Dirix, L. Y., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.01.011 · Cited by 143
Conery, A. R., Centore, R. C., Neiss, A., Keller, P. J., Joshi, S., Spillane, K. L., Sandy, P., Hatton, C., Pardo, E., Zawadzke, L. E., et al. (2016) · eLife · doi:10.7554/elife.10483 · Cited by 141
Welti, J. C., Rodrigues, D. N., Sharp, A., Sun, S., Lorente, D., Riisnaes, R., Figueiredo, I., Zafeiriou, Z., Rescigno, P., Bono, J. S. D., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.03.049 · Cited by 123
Self-citationLiu, J., He, D., Cheng, L., Huang, C., Zhang, Y., Rao, X., Kong, Y., Liu, J., Zhang, Z., Liu, J., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1270-z · Cited by 117
Decker, K. F., Zheng, D., He, Y., Bowman, T. A., Edwards, J. R., & Li, J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks888 · Cited by 115
Todenhöfer, T., Azad, A., Stewart, C., Gao, J., Eigl, B. J., Gleave, M. E., Joshua, A. M., Black, P. C., & Chi, K. N. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.06.094 · Cited by 111
Ianculescu, I., Wu, D., Siegmund, K. D., & Stallcup, M. R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.300194 · Cited by 110
Comuzzi, B., Nemes, C., Schmidt, S. U., Jasarevic, Z., Lodde, M., Pycha, A., Bartsch, G. H., Offner, F. A., Čulig, Z., & Hobisch, A. (2004) · The Journal of Pathology · doi:10.1002/path.1609 · Cited by 109
Qu, F., Xie, W., Nakabayashi, M., Zhang, H., Jeong, S. H., Wang, X., Komura, K., Sweeney, C. J., Sartor, O. A., Lee, G. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1070 · Cited by 108
Cai, L., Tsai, Y., Wang, P., Wang, J., Li, D., Fan, H., Zhao, Y., Bareja, R., Lu, R., Wilson, E. M., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.08.029 · Cited by 95
Androgen receptor profiling predicts prostate cancer outcome
Stelloo, S., Nevedomskaya, E., Poel, H. G., Jong, J., Leenders, G. J., Jenster, G., Wessels, L., Bergman, A., & Zwart, W. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505424 · Cited by 94
The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer
Yan, Y., Ma, J., Wang, D., Lin, D., Pang, X., Wang, S., Zhao, Y., Shi, L., Xue, H., Pan, Y., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910659 · Cited by 93
Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells
Wang, G., Jones, S. J. M., Marra, M. A., & Sadar, M. D. (2006) · Oncogene · doi:10.1038/sj.onc.1209715 · Cited by 80
Methylation specifies distinct estrogen-induced binding site repertoires of CBP to chromatinPreprint
Ceschin, D. G., Walia, M., Wenk, S. S., Duboé, C., Gaudon, C., Xiao, Y., Fauquier, L., Sankar, M., Vandel, L., & Gronemeyer, H. (2011) · Genes & Development · doi:10.1101/gad.619211 · Cited by 79
Isharwal, S., Miller, M. C., Marlow, C., Makarov, D. V., Partin, A. W., & Veltri, R. W. (2008) · The Prostate · doi:10.1002/pros.20772 · Cited by 71
Dynamic assembly and activation of estrogen receptor α enhancers through coregulator switching
Murakami, S., Nagari, A., & Kraus, W. L. (2017) · Genes & Development · doi:10.1101/gad.302182.117 · Cited by 70
Zhu, Y., Sharp, A., Anderson, C. M., Silberstein, J. L., Taylor, M. N., Lu, C., Zhao, P., Marzo, A. M. D., Antonarakis, E. S., Wang, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.08.009 · Cited by 65
Self-citationColeman, D. J., Gao, L., Schwartzman, J. A., Korkola, J. E., Sampson, D., Derrick, D. S., Urrutia, J. A., Balter, A. I., Burchard, J., King, C. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40518-5 · Cited by 41
Guedes, L. B., Morais, C. L., Almutairi, F., Haffner, M. C., Zheng, Q., Isaacs, J. T., Antonarakis, E. S., Lu, C., Tsai, H. K., Luo, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0205 · Cited by 39
Cell-cycle coupled expansion of AR activity promotes cancer progression
McNair, C., Urbanucci, A., Comstock, C., Augello, M. A., Goodwin, J. F., Launchbury, R., Zhao, S. G., Schiewer, M., Ertel, A., Karnes, J., et al. (2016) · Oncogene · doi:10.1038/onc.2016.334 · Cited by 38
Self-citationThe Role of the Transcriptional Coactivator p300 in Prostate Cancer Progression
Heemers, H. V., Debes, J. D., & Tindall, D. J. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_54 · Cited by 37
Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies
Dylgjeri, E., McNair, C. M., Goodwin, J. F., Raymon, H. K., McCue, P. A., Shafi, A. A., Leiby, B. E., de Leeuw, R., Kothari, V., McCann, J. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2207 · Cited by 35
Self-citationp300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer
Gruber, M., Ferrone, L., Puhr, M., Santer, F. R., Furlan, T., Eder, I. E., Sampson, N., Schäfer, G., Handle, F., & Čulig, Z. (2020) · Endocrine Related Cancer · doi:10.1530/erc-19-0488 · Cited by 29
Katavolos, P., Cain, G. R., Farman, C. A., Romero, F. A., Magnuson, S. R., Ly, J. Q., Choo, E. F., Katakam, A. K., Andaya, R., & Maher, J. M. (2020) · Toxicologic Pathology · doi:10.1177/0192623319898469 · Cited by 24
Sharp, A., Porta, N., Lambros, M. B. K., Welti, J. C., Paschalis, A., Raj, G. V., Plymate, S. R., & Bono, J. S. D. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01104 · Cited by 12
Self-citation
Cited by
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
Chen, Q., Yang, B., Liu, X., Zhang, X. D., Zhang, L., & Liu, T. (2022) · Theranostics · doi:10.7150/thno.73223 · Cited by 261
HER3 Is an Actionable Target in Advanced Prostate Cancer
Gil, V., Miranda, S., Riisnaes, R., Gurel, B., D’Ambrosio, M., Vasciaveo, A., Crespo, M., Ferreira, A., Brina, D., Troiani, M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-3360 · Cited by 68
Self-citationAcetyl-CoA metabolism as a therapeutic target for cancer
Chen, G., Bao, B., Cheng, Y., Tian, M., Song, J., Zheng, L., & Tong, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115741 · Cited by 54
Metadata
- Authors
- Welti, J., Sharp, A., Brooks, N., Yuan, W., McNair, C., Chand, S. N., Pal, A., Figueiredo, I., Riisnaes, R., Gurel, B., Rekowski, J., Bogdan, D., West, W., Young, B., Raja, M., Prosser, A., Lane, J., Thomson, S., Worthington, J., Onions, S., Shannon, J., Paoletta, S., Brown, R., Smyth, D., Harbottle, G. W., Gil, V. S., Miranda, S., Crespo, M., Ferreira, A., Pereira, R., Tunariu, N., Carreira, S., Neeb, A. J., Ning, J., Swain, A., Taddei, D., SU2C/PCF International Prostate Cancer Dream Team, Schiewer, M. J., Knudsen, K. E., Pegg, N., & de Bono, J. S.
- Venue
- Cancer Discovery
- Published
- 2021-01-11
- Volume
- 11
- Issue
- 5
- Pages
- 1118-1137
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3119572339
- Cited by
- 275
- References
- 66
- FWCI
- 24.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.